Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib vs Osimertinib + WBI in EGFR+ NSCLC with Brain Mets
NCT04829019Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of osimertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Neurocognitive function (HVLT-R) at 4 months. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04829019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04829019.